ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer

被引：0
|
作者：
Punie, K. [1 ,2 ]
Matikas, A. [3 ,4 ]
机构：
[1] Univ Hosp Leuven, Dept Gen Med Oncol, Herestr 49, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium
[3] Karolinska Inst, Oncol Pathol Dept, Stockholm, Sweden
[4] Karolinska Univ Hosp, Breast Ctr, Theme Canc, Stockholm, Sweden
来源：
ESMO OPEN | 2021年 / 6卷 / 01期
关键词：
D O I：
10.1016/j.esmoop.2020.100017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immune checkpoint inhibition in early-stage triple-negative breast cancer
    Varma, Revati
    Wright, Matthew
    Abraham, Jame
    Kruse, Megan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1225 - 1238
  • [22] Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients
    Nishio, Minako
    Kojitani, Yoshiki
    Kitashiro, Saya
    Ishiduka, Yasunobu
    Otsuka, Tomoyuki
    Nishida, Naohiro
    Fujisawa, Fumie
    Sugimoto, Naotoshi
    Yagi, Toshinari
    Souma, Ai
    Kanaoka, Haruka
    Oyamayama, Yuri
    Taniguchi, Azusa
    Nakajima, Satomi
    Seto, Yukiko
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nakayama, Takahiro
    Kudou, Toshihiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1465 - S1465
  • [23] HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer
    Barberio, Manuela Terranova
    Thomas, Scott
    Ali, Niwa
    Pawlowska, Nela
    Park, Jeenah
    Rosenblum, Michael D.
    Budillon, Alfredo
    Munster, Pamela N.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [24] Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
    Quintana, A.
    Saini, K. S.
    Vidal, L.
    Peg, V.
    Slebe, F.
    Loibl, S.
    Curigliano, G.
    Schmid, P.
    Cortes, J.
    ESMO OPEN, 2024, 9 (10)
  • [25] The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Singh, Sima
    Numan, Arshid
    Maddiboyina, Balaji
    Arora, Saahil
    Riadi, Yassine
    Md, Shadab
    Alhakamy, Nabil A.
    Kesharwani, Prashant
    DRUG DISCOVERY TODAY, 2021, 26 (07) : 1721 - 1727
  • [26] Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way
    Telli, M. L.
    Vinayak, S.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 347 - 348
  • [27] ZNF689 deficiency promotes intratumor heterogeneity and resistance to immune checkpoint blockade in triple-negative breast cancer
    Ge, Li-Ping
    Jin, Xi
    Di, Gen-Hong
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer
    Wu, Wenxin
    Xu, Ming
    Qiao, Bin
    Huang, Tongyi
    Guo, Huanling
    Zhang, Nan
    Zhou, Luyao
    Li, Manying
    Tan, Yang
    Zhang, Minru
    Xie, Xiaoyan
    Shuai, Xintao
    Zhang, Chunyang
    ACTA BIOMATERIALIA, 2023, 158 : 547 - 559
  • [29] ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
    Xu, Chao
    Xie, Yongjie
    Xie, Peng
    Li, Jianming
    Tong, Zhongsheng
    Yang, Yanfang
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [30] CD47 BLOCKADE MODULATES IMMUNOSUPPRESSIVE CHECKPOINT MOLECULES AND CELLULAR METABOLISM TO SENSITIZE TRIPLE-NEGATIVE BREAST CANCER TUMORS TO IMMUNE CHECKPOINT BLOCKADE THERAPY
    Stirling, Elizabeth
    Wilson, Adam
    Cook, Katherine
    Thomas, Alexandra
    Triozzi, Pierre
    Soto-Pantoja, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A646 - A646
12345